STOCK TITAN

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PureTech Health (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company focused on developing treatments for devastating diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Bharatt Chowrira will deliver a presentation on Wednesday, January 15, 2025, at 11:15am PST / 2:15pm EST. The presentation will be accessible to investors and interested parties through a webcast available on the company's investor relations website.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), una società di bioterapia in fase clinica focalizzata sullo sviluppo di trattamenti per malattie devastanti, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference. Il CEO Bharatt Chowrira presenterà un intervento il mercoledì 15 gennaio 2025, alle 11:15 PST / 14:15 EST. La presentazione sarà accessibile a investitori e parti interessate tramite una webconferenza disponibile sul sito web delle relazioni con gli investitori dell'azienda.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), una empresa de bioterapias en etapa clínica centrada en el desarrollo de tratamientos para enfermedades devastadoras, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. El CEO Bharatt Chowrira realizará una presentación el miércoles 15 de enero de 2025, a las 11:15 am PST / 2:15 pm EST. La presentación será accesible para inversores y partes interesadas a través de una transmisión en vivo disponible en el sitio web de relaciones con inversores de la empresa.

PureTech Health (Nasdaq: PRTC, LSE: PRTC)는 파괴적인 질병을 치료하기 위한 개발에 중점을 두고 있는 임상 단계의 생물요법 회사로, 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. CEO Bharatt Chowrira2025년 1월 15일 수요일 오전 11:15 PST / 오후 2:15 EST에 발표를 진행할 예정입니다. 발표는 투자자와 이해관계자들이 기업의 투자자 관계 웹사이트에서 제공되는 웹캐스트를 통해 접근할 수 있습니다.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), une entreprise biopharmaceutique en phase clinique axée sur le développement de traitements pour des maladies dévastatrices, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Le PDG Bharatt Chowrira fera une présentation le mercredi 15 janvier 2025, à 11h15 PST / 14h15 EST. La présentation sera accessible aux investisseurs et aux parties intéressées via un webinaire disponible sur le site de relations investisseurs de l'entreprise.

PureTech Health (Nasdaq: PRTC, LSE: PRTC), ein biotherapeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für devastierende Krankheiten konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference angekündigt. CEO Bharatt Chowrira wird am Mittwoch, dem 15. Januar 2025, um 11:15 Uhr PST / 14:15 Uhr EST eine Präsentation halten. Die Präsentation wird Investoren und Interessierten über ein Webcast, der auf der Investor-Relations-Website des Unternehmens verfügbar ist, zugänglich sein.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Bharatt Chowrira, PhD, JD, Chief Executive Officer, will present at the 43rd annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15am PST / 2:15pm EST. A webcast of the presentation will be available at https://investors.puretechhealth.com.

About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com



UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com



US Media

Justin Chen

+1-609-578-7230

jchen@tenbridgecommunications.com

Source: PureTech Health plc

FAQ

When is PureTech (PRTC) presenting at the 2025 J.P. Morgan Healthcare Conference?

PureTech (PRTC) will present at the J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15am PST / 2:15pm EST.

How can investors watch PureTech's (PRTC) J.P. Morgan Healthcare Conference presentation?

Investors can watch PureTech's presentation via webcast through the company's investor relations website at https://investors.puretechhealth.com.

Who will represent PureTech (PRTC) at the 2025 J.P. Morgan Healthcare Conference?

Bharatt Chowrira, PhD, JD, Chief Executive Officer of PureTech, will represent the company at the conference.

Which stock exchanges is PureTech (PRTC) listed on?

PureTech is dual-listed on the Nasdaq (PRTC) and London Stock Exchange (LSE: PRTC).

PureTech Health plc American Depositary Shares

NASDAQ:PRTC

PRTC Rankings

PRTC Latest News

PRTC Stock Data

421.38M
23.94M
0.13%
0.08%
Biotechnology
Healthcare
Link
United States of America
Boston